Lung Transplantation for Pleuroparenchymal Fibroelastosis

• Conditions: Fibroelastosis

• Registration Number: NCT05044390
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

This retrospective observational study will evaluate the outcomes of lung transplantation for a rare cause of interstitial lung disease called pleuroparenchymal fibroelastosis. Data will be collected from all transplantation center in France.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-04-01
• Primary Completion: 2021-07-01
• Status Verified: 2021-08
• Study First Submitted: 2021-08-30
• Study First Submitted QC: 2021-09-06
• Last Update Submitted: 2021-09-06
• Study First Posted: 2021-09-14
• Last Update Posted: 2021-09-14
• Study Completion: 2021-11-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Lung transplantation (any type) for pleuroparenchymal fibroelastosis
• Histologically confirmed pleuroparenchymal fibroelastosis on the recipient lungs

Exclusion Criteria

• All other interstitial lung disease than pleuroparenchymal fibroelastosis
• Pleuroparenchymal fibroelastosis who didn't underwent lung transplantation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Post-operative mortality	Any death up to 90 days after lung transplantation	Any death after lung transplantation during the first 30 days or during the hospitalization following the lung transplantation (in-hospital mortality)

Trial Locations

Locations (4)

Marie Lannelongue Hospital; 🇫🇷 Le Plessis-Robinson, France

Hopital Louis Pradel; 🇫🇷 Lyon, France

Bichat Claude Bernard Hospital, APHP; 🇫🇷 Paris, France

Foch Hospital; 🇫🇷 Suresnes, France